Cynvenio Announces Availability of Concordia, a New Cell-free DNA Purification Upgrade for its LiquidBiopsy Whole Blood Enrichment Platform
Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for all cancer patients, recently announced the availability of the ConcordiaT cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsyR platform. When coupled with Thermo Fisher Scientific’s Ion TorrentT next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of
tumor cell DNA for cancer research samples from a standard blood draw.
The Concordia option, which consists of a hardware module and a software upgrade, is now available to early access customers through the company’s partnership with Thermo Fisher Scientific. The module is easily installed by users on LiquidBiopsy units already deployed in clinical research labs, and the software upgrade is installed remotely. Cynvenio’s cfDNA upgrade package enables users to purify DNA from whole blood using Thermo Fisher’s Applied BiosystemsT MagMAXT Cell-Free DNA Isolation Kit, an integrated system designed to simplify, standardize, and accelerate preparation of samples derived from various sources for downstream molecular analysis.
Full commercial release of the upgrade kit is scheduled for the second quarter of this year.
“Our LiquidBiopsy platform is the first and only automated enrichment system to produce multiple templates from a single blood sample for downstream molecular characterization by next-generation sequencing,” said Paul Dempsey, Chief Science Officer of Cynvenio. “Our approach enables clinical researchers to simultaneously sequence circulating tumor DNA as well as DNA from circulating tumor cells (CTCs) for the most comprehensive readout of tumor variants. Providing automated multi-template sample preparation on our platform simplifies lab workflows and ensures quality nucleic acid material for downstream analysis. Moreover, we expect this technology will help better inform patient care in the future.”
Jason Johnson, Senior Director, oncology product management in the clinical sequencing business at Thermo Fisher Scientific, commented: “We strive to provide our customers with the best automated solutions to enhance their clinical research and simplify lab workflows. We are very pleased to offer Cynvenio’s Concordia upgrade to our LiquidBiopsy platform customers, enabling greater workflow efficiencies with their research by allowing them to achieve multi-template sample preparation of cfDNA and CTCs on a single instrument.”
More information about Cynvenio and the LiquidBiopsy platform is available at www.cynvenio.com.
About Cynvenio Biosystems, Inc.
Cynvenio is a commercial stage clinical diagnostics company that leverages its proprietary LiquidBiopsyR multi-template technology for the molecular characterization of tumor cells from a standard blood draw. Commercial labs and research institutions are powered by Cynvenio’s LiquidBiopsy platform, which includes automated instrumentation, consumables/reagents, patient sample kits, and bioinformatics for sequencing rare cell populations. Oncology practices and individual physicians can also access the LiquidBiopsy technology by ordering the ClearIDT blood test from Cynvenio’s CLIA/CAP lab or its clinical partners. ClearID and LiquidBiopsy are used to rapidly assess patients’ evolving mutations in support of precision medicine strategies. ClearID is reimbursable in the United States.
Cynvenio is headquartered in Westlake Village, California (Los Angeles).
For more information, please visit http://www.cynvenio.com and www.liquidbiopsy.com.
LiquidBiopsyR is a registered trademark and ClearIDT is a trademark of Cynvenio Biosystems, Inc.
MagMAXT is a trademark of Thermo Fisher Scientific.
Source: Cynvenio
